论文部分内容阅读
目的观察盐酸吡格列酮联合二甲双胍治疗初发2型糖尿病(T2DM)患者的疗效和安全性。方法新诊断T2DM患者76例随机分成治疗组39例及对照组37例,治疗组予盐酸吡格列酮15 mg/d联合二甲双胍0.25 g口服每天3次,对照组予二甲双胍0.5 g口服每天3次,均治疗3个月,观察2组治疗前后空腹及餐后2 h血糖(FBG,2hPBG)、糖化血红蛋白(HbA1c)、胰岛素(Ins)、稳态模型胰岛素抵抗(HomaIR)指数、血脂、体质量指数(BMI)的变化。结果治疗组和对照组治疗后血糖、HbA1c、HomaIR均较治疗前明显下降,血脂代谢得到改善,并且有统计学意义。治疗组的血糖、HbA1c、HomaIR及血脂改善优于对照组。对照组BMI较治疗前下降,治疗组没有明显变化。结论盐酸吡格列酮联合二甲双胍治疗初发T2DM患者的糖脂代谢及胰岛素抵抗的改善优于单用二甲双胍。
Objective To observe the efficacy and safety of pioglitazone hydrochloride plus metformin in the treatment of patients with newly diagnosed type 2 diabetes mellitus (T2DM). Methods A total of 76 newly diagnosed T2DM patients were randomly divided into treatment group (n = 39) and control group (n = 37). The patients in the treatment group were treated with pioglitazone hydrochloride 15 mg / d and metformin 0.25 g orally three times a day, and the control group with metformin 0.5 g orally three times daily (FBG, HbA1c, Ins, HomaIR index, blood lipid, body mass index (BMI)) of two groups were observed before and after treatment for 3 months. )The change. Results After treatment, the blood glucose, HbA1c and HomaIR in the treatment group and the control group were significantly lower than those before treatment, and the blood lipid metabolism was improved, and there was statistical significance. The treatment group, blood glucose, HbA1c, HomaIR and blood lipid better than the control group. The BMI in the control group decreased compared with that before treatment, and there was no significant change in the treatment group. Conclusion Pioglitazone hydrochloride plus metformin is superior to metformin alone in improving the glucose and lipid metabolism and insulin resistance in newly diagnosed T2DM patients.